Hasten Biopharma and Sinopharm Group Jiangsu Company Limited signed a strategic cooperation agreement in Suzhou Jiangsu Province on September 27th 2022. The two companies will work together to create a closed-loop medical service by using innovative digital marketing methods, enhance the coverage of digital platform through the efficient commercialization capability of Sinopharm Jiangsu, and assist patients in the whole course of health management.

Hasten Bioparma and Jointown Pharmaceutical Group Co. (Jointown Group) signed a strategic cooperation agreement. The two companies will work together to build an out-of-hospital chronic disease management ecosystem, enhance retail terminal coverage through efficient commercialization capabilities, improve out-of-hospital patient access to medicines, and work together to benefit more patients with chronic diseases.

In recent years, the number of incidences, illnesses and mortality by chronic diseases has been increasing, and chronic diseases such as cardiovascular and cerebrovascular diseases are a serious threat to the health of Chinese people, especially the elderly population, making it particularly important to focus on the unmet needs of chronic diseases.

- CBC Group further builds global healthcare platform to address unmet medical needs

- Hasten Biopharma accelerates its layout to provide more innovative drugs to Chinese patients